Alpha-Lipoic Acid (ALA) for Alzheimer's Disease
Also known as: ALA, Thioctic acid, R-lipoic acid
ALA addresses insulin resistance and oxidative stress — two convergent pathological features in Alzheimer's disease.
Mechanism of Action
ALA improves cerebral glucose utilization by enhancing insulin signaling, chelates iron accumulated in AD brain regions, and regenerates glutathione depleted by amyloid-induced oxidative stress. It also inhibits tau hyperphosphorylation via GSK3β modulation.
General mechanism: Universal antioxidant and mitochondrial cofactor. Regenerates other antioxidants, chelates metals, enhances pyruvate dehydrogenase activity.
Current Evidence
Small clinical trials show stabilization of cognitive decline over 48 months with ALA + omega-3 combination. ADAS-cog scores improved vs natural progression. Larger trials needed.
Clinical Status: Phase II trials positive. Available as supplement. Combination studies ongoing.
Safety Profile
Very safe orally. IV use requires medical supervision. Hypoglycemia risk in diabetics. Rare: autoimmune insulin syndrome in susceptible individuals.
Key Research Questions
- Can ALA prevent AD in type 2 diabetes patients?
- Does ALA's metal chelation reduce amyloid-iron toxicity?